Newport Coast, CA – According to filings with the U.S. Securities and Exchange Commission, VivoSense is raising $25,000,000.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Dudley Tabakin played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About VivoSense
VivoSense is the world leader in data analysis consulting and software, specializing in wearable sensor physiological monitoring solutions for clinical trials, healthcare research, and consumer wellness. VivoSense develops regulatory compliant digital biomarkers using the data from wearable sensors. Digital biomarkers are used to accurately measure drug and treatment effects in patients in regulated clinical trials and healthcare research. VivoSense is the first analytics company to develop novel digital biomarkers from wearable sensor data, which constitute primary and secondary clinical endpoints in regulated international pharmaceutical trials. Several of these studies are in rare disease indication and have reached the open-label phase of development at top-ten pharma.

To learn more about VivoSense, visit http://www.vivosense.com/

Contact:
Dudley Tabakin, Chief Executive Officer
949-933-3429
https://www.linkedin.com/in/dudleytabakin/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved